NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

神經芽腫:流行病學的預測(2027年)

Neuroblastoma (NB)- Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 534925
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 2-10個工作天內
價格
神經芽腫:流行病學的預測(2027年) Neuroblastoma (NB)- Epidemiology Forecast to 2028
出版日期: 按訂單生產內容資訊: 英文 50 Pages
簡介

主要7個國家神經芽腫的罹患數,2016年推定為約1,530人。

本報告提供神經芽腫的相關調查,總括性彙整疾病概要,患者背景,主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的罹患數趨勢,今後10年流行病學的預測,成長要素及市場障礙,今後市場機會等資訊。

目錄

第1章 重要洞察

第2章 疾病背景和概要

第3章 簡介

  • 神經芽腫的分期
    • 神經芽腫的國際病期分類系統(INSS)
    • 國際神經芽腫風險分類系統(INRGSS)
  • 神經芽腫的風險群
  • 徵兆與症狀
  • 危險因素
  • 病理生理學
  • 治療標的
  • 診斷

第4章 流行病學和患者人口

第5章 主要觀察

第6章 人口與預測參數

第7章 主要7個國家神經芽腫的罹患數

第8章 神經芽腫的流行病學:各國

  • 美國
    • 神經芽腫的整體罹患數
    • 神經芽腫的罹患數:風險群
  • 歐盟5國
    • 德國
      • 神經芽腫的整體罹患數
      • 神經芽腫的罹患數:風險群
    • 法國
      • 神經芽腫的整體罹患數
      • 神經芽腫的罹患數:風險群
    • 英國
      • 神經芽腫的整體罹患數
      • 神經芽腫的罹患數:風險群
    • 西班牙
      • 神經芽腫的整體罹患數
      • 神經芽腫的罹患數:風險群
    • 義大利
      • 神經芽腫的整體罹患數
      • 神經芽腫的罹患數:風險群
  • 日本
    • 神經芽腫的整體罹患數
    • 神經芽腫的罹患數:風險群

第9章 附錄

第10章 調查手法

第11章 DelveInsight的服務內容

第12章 免責聲明

第13章 關於DelveInsight

目錄
Product Code: DIEI0149

DelveInsight's 'Neuroblastoma (NB)- Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of HSV infections in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2028

Neuroblastoma Epidemiology

The Neuroblastoma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Neuroblastoma are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Neuroblastoma Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total incident population and incident cases by risk groups (Low risk, intermediate risk and high risk)] of Neuroblastoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, total incident cases of Neuroblastoma in 7 major markets is found to be about 1530 in 2016.

Report Scope

  • The report covers detailed overview of Neuroblastoma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Neuroblastoma in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by risk groups (low, intermediate and high risk group) in 7MM

Key strengths

  • 10 Year Forecast of Neuroblastoma epidemiology
  • 7MM Coverage
  • Total Incident Cases of Neuroblastoma
  • Incident Cases according to segmentation: Neuroblastoma cases by risk groups (low, intermediate and high risk group) in 7MM

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. KEY INSIGHTS

2. DISEASE BACKGROUND AND OVERVIEW

3. INTRODUCTION

  • 3.1. STAGES OF NEUROBLASTOMA
    • 3.1.1. International Neuroblastoma Staging System (INSS)
    • 3.1.2. International Neuroblastoma Risk Group Staging System (INRGSS)
  • 3.2. NEUROBLASTOMA RISK GROUPS
    • 3.2.1. Children's Oncology Group (COG) Risk Group Classification
    • 3.2.2. International Neuroblastoma Risk Group (INRG) classification
    • 3.2.3. COG and INRG Classifications
    • 3.2.4. Current COG Neuroblastoma Risk Stratification
  • 3.3. SIGNS AND SYMPTOMS
  • 3.4. ETIOLOGY
  • 3.5. PATHOGENESIS
  • 3.6. THERAPEUTIC TARGETS FOR NEUROBLASTOMA
  • 3.7. DIAGNOSIS

4. EPIDEMIOLOGY AND PATIENT POPULATION

5. KEY FINDINGS

6. POPULATION AND FORECAST PARAMETERS

7. 7MM TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA

8. COUNTRY WISE-EPIDEMIOLOGY OF NEUROBLASTOMA

  • 8.1. United States
    • 8.1.1. Total Incident Patient Population of Neuroblastoma in the United States
    • 8.1.2. Distribution of Incident cases by Risk Groups - Neuroblastoma
  • 8.2. EU5 Countries
  • 8.3. Germany
    • 8.3.1. Total Incident Patient Population of Neuroblastoma in Germany
    • 8.3.2. Distribution of Incident cases by Risk Groups - Neuroblastoma
  • 8.4. France
    • 8.4.1. Total Incident Patient Population of Neuroblastoma in France
    • 8.4.2. Distribution of Incident cases by Risk Groups - Neuroblastoma
  • 8.5. United Kingdom
    • 8.5.1. Total Incident Patient Population of Neuroblastoma in the United Kingdom
    • 8.5.2. Distribution of Incident cases by Risk Groups - Neuroblastoma
  • 8.6. Spain
    • 8.6.1. Total Incident Patient Population of Neuroblastoma in Spain
    • 8.6.2. Distribution of Incident cases by Risk Groups - Neuroblastoma
  • 8.7. Italy
    • 8.7.1. Total Incident Patient Population of Neuroblastoma in Italy
    • 8.7.2. Distribution of Incident cases by Risk Groups - Neuroblastoma
  • 8.8. Japan
    • 8.8.1. Total Incident Patient Population of Neuroblastoma in Japan
    • 8.8.2. Distribution of Incident cases by Risk Groups - Neuroblastoma

9. APPENDIX

10. REPORT METHODOLOGY

  • 10.1. Sources used

11. DELVEINSIGHT CAPABILITIES

12. DISCLAIMER

13. ABOUT DELVEINSIGHT

List of Tables

TABLE 1: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE 7MM (2016-2028)

TABLE 2: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED STATES (2016-2028)

TABLE 3: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED STATES (2016-2028)

TABLE 4: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN GERMANY (2016-2028)

TABLE 5: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN GERMANY (2016-2028)

TABLE 6: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN FRANCE (2016-2028)

TABLE 7: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN FRANCE (2016-2028)

TABLE 8: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED KINGDOM (2016-2028)

TABLE 9: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED KINGDOM (2016-2028)

TABLE 10: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN SPAIN (2016-2028)

TABLE 11: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN SPAIN (2016-2028)

TABLE 12: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN ITALY (2016-2028)

TABLE 13: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN ITALY (2016-2028)

TABLE 14: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN JAPAN (2016-2028)

TABLE 15: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN JAPAN (2016-2028)

List of Figures

FIGURE 1: STAGING OF NEUROBLASTOMA

FIGURE 2: SIGNS AND SYMPTOMS OF NEUROBLASTOMA

FIGURE 3: PATHOGENESIS OF NEUROBLASTOMA

FIGURE 4: THERAPEUTIC TARGETS FOR NEUROBLASTOMA

FIGURE 5: INITIAL DIAGNOSTIC WORK FOR NEUROBLASTOMA

FIGURE 6: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE 7MM (2016-2028)

FIGURE 7: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED STATES (2016-2028)

FIGURE 8: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED STATES (2016-2028)

FIGURE 9: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN GERMANY (2016-2028)

FIGURE 10: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN GERMANY (2016-2028)

FIGURE 11: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN FRANCE (2016-2028)

FIGURE 12: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN FRANCE (2016-2028)

FIGURE 13: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN THE UNITED KINGDOM (2016-2028)

FIGURE 14: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN THE UNITED KINGDOM (2016-2028)

FIGURE 15: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN SPAIN (2016-2028)

FIGURE 16: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN SPAIN (2016-2028)

FIGURE 17: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN ITALY (2016-2028)

FIGURE 18: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN ITALY (2016-2028)

FIGURE 19: TOTAL INCIDENT PATIENT POPULATION OF NEUROBLASTOMA IN JAPAN (2016-2028)

FIGURE 20: INCIDENT PATIENT POPULATION OF NEUROBLASTOMA BY RISK GROUPS IN JAPAN (2016-2028)